Company: CERO
Filing Date: 2025-05-02
Form Type: PRER14A
Source: 0001213900-25-039149
Chunk: 58

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-05-02
Form: PRER14A
Chunk 58
---
 proxy and entitled to vote at the Annual Meeting will be required to approve this proposal. Abstentions and broker non -voteswill have no effect on the outcome of this proposal.

| THE BOARD UNANIMOUSLY RECOMMENDS A VOTE “FOR” THE ELECTION OF EACH OF MICHAEL BYRNES AND LINDSEY ROLFE AS THE CLASS I DIRECTORS, TO SERVE FOR A THREE-YEAR TERM ENDING AT THE ANNUAL MEETING OF STOCKHOLDERS TO BE HELD IN 2028. |     | ü |

Directors Continuing in Office The following table and narrative information identify our directors continuing in office, and sets forth their principal occupation and business experience during the last five years and their ages as of May1, 2025.

| Name             |     | Age |     | Title                                       |     | Class and Year in 
 Which Term        
 Will Expire       |     | Director 
    Since |
| Brian G. Atwood  |     |  72 |     | Director                                    |     | Class II – 2026   |     |     2024 |
| Kathleen LaPorte |     |  63 |     | Director                                    |     | Class II – 2026   |     |     2024 |
| Shami Patel      |     |  56 |     | Director                                    |     | Class III – 2027  |     |     2024 |
| Chris Ehrlich    |     |  55 |     | Chairman, Chief Executive Officer, Director |     | Class III – 2027  |     |     2024 |

Class II Directors (Term Expires at 2026 Annual Meeting) Brian G. Atwoodpreviously served as Chairman and Chief Executive Officer of CERo from February 2024 to September 2024, and previously served as Chairman of PBAX from October 2021 until the closing of the Business Combination in February 2024. Mr. Atwood serves as a Managing Director for Versant Ventures, a healthcare -focusedventure capital firm that he co -foundedin 1999. In 2015, Mr. Atwood co -foundedCell Design Labs, Inc., a biotechnology company focused on developing human cell engineering technology for the treatment of multiple diseases, including cancer, where he served as President and Chief Executive Officer until 2017, when it was acquired by Gilead Sciences. Mr. Atwood has served on